In a Nod to Precision Oncology, the FDA Approves RevumenibByKevin Le, PharmD, BCOP,Ayaa Kobaissi, PharmD Candidate,Eugenia Kwon, PharmD Candidate,Maidah Farooq,Ami Ali, PharmD, BCOPFebruary 12th 2025The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.